Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | CCR8 | P51685 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16235635 | 0.81 | NR4A2 (0.47) | NR4A2KDM4EMAPTMETAP1CCR1 | |
| SCHEMBL31329846 | 0.81 | NR4A2 (0.56) | NR4A2KDM4EMAPTCCR1CCR8 | |
| Quinoline SCHEMBL28210108 | 0.80 | ALDH1A1 (0.57) | NR4A2KDM4EMAPTMETAP1CCR1 | |
| SCHEMBL30133446 | 0.77 | SYK (0.55) | NR4A2KDM4EMAPTCYP3A4LMNA | |
| SCHEMBL26130603 | 0.77 | SYK (0.55) | NR4A2KDM4EMAPTCYP3A4LMNA | |
| SCHEMBL30023109 | 0.75 | LMNA (0.46) | NR4A2KDM4EMAPTMETAP1L3MBTL1 | |
| SCHEMBL22201437 | 0.75 | PRKCH (0.56) | NR4A2KDM4EMAPTMETAP1ALDH1A1 | |
| SCHEMBL31170791 | 0.73 | NR4A2 (0.52) | NR4A2KDM4EMAPTMETAP1CCR1 | |
| SCHEMBL18529914 | 0.72 | KDM4E (0.35) | NR4A2KDM4EMETAP1CYP3A4LMNA | |
| SCHEMBL523735 | 0.72 | MAPT (0.58) | NR4A2KDM4EMAPTMETAP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617791-B2 | Triheterocyclic derivative, and pharmaceutical composition and application thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4230628-B1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
| US-12358931-B2 | 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| CN-116003441-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4504724-A1 | SPLEEN TYROSINE KINASE INHIBITORS | Uniquest Pty Limited (AU) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325474-A | Spleen tyrosine kinase inhibitors | 尤尼奎斯特公司 | 2025-01-17 | — | — | CN | disclosed |
| US-8633319-B2 | 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors | GLAXO GROUP LIMITED (GB) | 2014-01-21 | — | — | US | disclosed |
| EP-2563789-A1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | Glaxo Group Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| CN-102947306-A | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as SYK inhibitors | GLAXO GROUP LTD | 2013-02-27 | — | — | CN | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| WO-2011134971-A1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134971-A1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-7202249-B2 | Antagonists of chemokine receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20040048865-A1 | Antagonists of chemokine receptors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358931-B2 | 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor | JAK1, JAK3, JAK2 | NR4A2 2491/4885KDM4E 272/4885MAPT 4182/4885 |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | SYK, BTK, LYN | NR4A2 1801/4885KDM4E 629/4885MAPT 3202/4885 |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | NR4A2 27/4885KDM4E 2872/4885MAPT 4488/4885 |
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | NR4A2 1712/4885KDM4E 644/4885MAPT 3900/4885 |
| US-12617791-B2 | Triheterocyclic derivative, and pharmaceutical composition and application thereof | ATR, NR3C1, NR5A1 | NR4A2 45/4885KDM4E 3222/4885MAPT 4596/4885 |
| US-20040048865-A1 | Antagonists of chemokine receptors | CXCR2, CCR1, CXCR3 | NR4A2 209/4885KDM4E 3036/4885MAPT 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.